CN102816238A - IgG1 anti-human beta2-glycoprotein I monoclonal antibody, and preparation and application thereof - Google Patents

IgG1 anti-human beta2-glycoprotein I monoclonal antibody, and preparation and application thereof Download PDF

Info

Publication number
CN102816238A
CN102816238A CN2012102560047A CN201210256004A CN102816238A CN 102816238 A CN102816238 A CN 102816238A CN 2012102560047 A CN2012102560047 A CN 2012102560047A CN 201210256004 A CN201210256004 A CN 201210256004A CN 102816238 A CN102816238 A CN 102816238A
Authority
CN
China
Prior art keywords
gpi
monoclonal antibody
glycoprotein
antibody
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012102560047A
Other languages
Chinese (zh)
Inventor
周红
许国莹
胥亚
严金川
穆原
王婷
夏龙飞
解鸿翔
刘敬敬
张晓蕾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu University
Original Assignee
Jiangsu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu University filed Critical Jiangsu University
Priority to CN2012102560047A priority Critical patent/CN102816238A/en
Publication of CN102816238A publication Critical patent/CN102816238A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to an IgG1 anti-human beta2-glycoprotein I (beta2GPI) monoclonal antibody. The IgG1 anti-human beta2-glycoprotein I monoclonal antibody is secreted by the hybridoma cell line AB2-F6. The monoclonal antibody can react with beta2GPI prepared in the invention and is comparable with a standard anti-beta2GPI monoclonal antibody; the IgG1 anti-human beta2-glycoprotein I monoclonal antibody provided by the invention has strong specificity and is used for preparation of a double-antibody sandwich ELISA assay kit for human plasma beta2 glycoprotein I.

Description

The anti-people β of IgG1 type 2Glycoprotein I monoclonal antibody and preparation thereof and application
Technical field
The invention belongs to the antibody production techniques category, be used for the research field of relevant autoimmune disorder, be specifically related to anti-people β 2Glycoprotein I (β 2GPI) MONOCLONAL ANTIBODIES SPECIFIC FOR, evaluation and application.
Background note
Antiphospholipid syndrome (APS) is to be a kind of non-organ specificity autoimmune disorder of principal character to occur high titre anti-phospholipid antibody (APL) in the patient body, can fall ill separately, also can occur together with other autoimmune diseases, especially SLE.Its main clinical characters is repeatedly the artery and vein thrombosis, many organs ischemic and habitual abortion.APL is one group of cyclicity autoantibody that directly is directed against the heterogencity of negative charge phosphatide and albumen cofactor, mainly comprises lupus anticoagulant (LA), ACLA (aCL), anti-phosphatidylserine antibody and anti-phosphatidylethanolamine antibody.Discover that APL mainly discerns phospholipids incorporate albumen, rather than phosphatide itself, wherein, most important phospholipids incorporate albumen is β 2Glycoprotein I (β 2GPI), itself and corresponding antibodies (anti-β 2GPI) form mixture, in the APS pathologic process, play a significant role.International thrombus hemostasis association (ISTH) meeting that hold in Sydney in 2005 is augmented anti-β 2GPI antibody positive first as one of APS laboratory diagnosis index.
Anti-β 2GPI/ β 2The GPI mixture can make its secretion and discharge cell adhesion molecule, inflammatory factor, TF etc., and can stimulate blood mononuclear cell to express TF through activating vascular endothelial cell.TF is the strand gp through cytolemma, is the acceptor of serum prothrombin conversion accelerator(SPCA)/VIIa, and TF/VIIa activates plasma thromboplastin component, X with the form of mixture, thereby causes blood coagulation.Therefore, anti-β 2GPI/ β 2It is the thrombotic important mechanism of APS that GPI mixture inducing cell is expressed TF, but concrete mechanism of action is also demanded urgently inquiring into.β mainly is engaged in this laboratory 2GPI and antibody thereof stimulate the research of monocytic intracellular signal transmission mechanism, and then illustrate anti-β 2GPI/ β 2The keying action of GPI in APS thrombosis mechanism.Need use a large amount of β under study for action 2GPI and anti-β 2GPI, but also not anti-β on the present home market 2GPI sells, and abroad this antibody selling price is too high, and the Buying Cycle is long, restricts carrying out smoothly of research work.Therefore, prepare anti-β 2The GPI monoclonal antibody will be practiced thrift the time cost and the Financial cost of research greatly, establish good basis smoothly for the research work in this field, have the important use meaning.
β among the human normal plasma of domestic and international different bibliographical informations 2The level of GPI has difference slightly: 200 ± 35m g/L, 150 ~ 300m g/L, 50 ~ 150mgL etc. are arranged; The bibliographical information result very big reason that differs is that used detection method is different; Have plenty of with ELISA and detect, also have with radioimmunology, immunoelectrophoresis etc.Expect that unified result so at first must unify detection method.The present domestic β that also do not detect 2The test kit of GPI, so anti-β among the present invention 2The GPI MONOCLONAL ANTIBODIES SPECIFIC FOR is β 2Certain basis has been established in the preparation of GPI test kit, so that provide a unification to detect β for domestic 2The method of GPI.Bibliographical information is arranged recently, total β in APS patient's body 2The level of GPI is apparently higher than healthy and other autoimmune disorders collator, and compares β in APS patient's body with the normal healthy controls group 2GPI content raises, and β is explained in the also corresponding increase of its thrombotic risk 2The level of GPI and thrombotic risk have very big dependency.According to going back some bibliographical information, β 2GPI and numerous disease exist certain relation, various disease β 2GPI can show different the variation, like β in liver cirrhosis patient and disseminated intravascular coagulation patient body 2GPI reduces, and has family to assemble the patients with cerebral apoplexy β of tendency 2Increasing of GPI serum level, but concrete mechanism is not quite clear.To sum up, test kit according to the invention not only can be used for the prediction of APS patient's thrombosis risk but also can be used for Chinese population β 2Relation between the generaI investigation of GPI level and convenient research itself and other disease.
This laboratory is purified into β from human plasma 2GPI has also prepared anti-β 2The GPI polyclonal antibody (yellow loud and clear, Zhou Hong, Yu Ying, etc. the anti-people β of rabbit 2Gp I Polyclonal Antibody Preparation and evaluation [J]. Clinical Laboratory magazine .2009,27 (3): 192-194.), and carrying out the discussion work of APS mechanism of causing a disease in recent years always.Have high specificity in view of monoclonal antibody (MAbs), advantages such as highly sensitive and easy stdn, the present invention has prepared mouse-anti people β 2The GPI monoclonal antibody is also analyzed its characteristic, for deep Mechanism Study is laid a good foundation.In view of the existing anti-β in this laboratory 2The monoclonal antibody of GPI and how anti-the invention provides a kind of human plasma β 2GPI double-antibody sandwich elisa detection method and test kit.
Summary of the invention
β 2GPI is the gp of the about 45~50KD of molecular weight, and (I~V) form, liver are main synthesising parts to its structure by 5 CCP spline structure districts.Anti-β 2GPI/ β 2The effect of GPI mixture in the APS pathomechanism receives very big concern.Have high specificity in view of MAbs, advantages such as highly sensitive and easy stdn the object of the present invention is to provide anti-β 2The GPI monoclonal antibody, and at preparation detection β 2The double antibodies sandwich ELISA of GPI measures the application in the test kit.
The anti-people β of IgG1 type of the present invention 2The GPI monoclonal antibody is that the preserving number of said hybridoma cell line AB2-F6 is CCTCCNO:C201132 by hybridoma cell line AB2-F6 secretion.
The anti-people β of above-mentioned IgG1 type 2GPI MONOCLONAL ANTIBODIES SPECIFIC FOR method is: with the human plasma β of purifying 2GPI immunity BALB/c mouse adopts the PEG integration technology, indirect elisa method and limiting dilution assay, preparation and screening hybridoma.Be injected into BALB/c mouse after the hybridoma continuation enlarged culturing and prepare ascites, through ammonium sulfate precipitation and Protein G purifying MAbs.NST-757 prevents method to identify the hybridoma cell strain chromosome number, and ELISA measures titre, and Ig subclass test kit is identified the Ig subclass, and Western blot identifies specificity.
The present invention is with the human plasma β of purifying 2Mouse boosting cell after the GPI immunity and murine myeloma cell merge the hybridoma AB2-F6 that the back produces, and the excretory monoclonal antibody is the IgG1/Kappa type, its can with the β of this chamber preparation 2GPI reaction, and with the anti-β of standard 2The GPI monoclonal antibody has comparability, and the present invention has stronger specificity.
The invention also discloses the anti-people β of said IgG1 type 2The monoclonal antibody of glycoprotein I is at preparation human plasma β 2The double-antibody sandwich elisa of glycoprotein I is measured the application in the test kit.
A kind of human plasma β 2The double-antibody sandwich elisa of glycoprotein I is measured test kit, by anti-β 2The elisa plate that the GPI polyclonal antibody encapsulates, 10% foetal calf serum confining liquid, anti-β 2GPI monoclonal antibody, HRP-sheep anti-mouse igg, colour developing liquid and stop buffer are formed.The liquid that wherein develops the color comprises A liquid: H 2O 2B liquid: TMB (TMB).
Above-mentioned detection β 2The preparation method that the double antibodies sandwich ELISA of GPI measures test kit is: through to chessboard titration confirm β 2The confirming of GPI list/polyclonal antibody and HRP-sheep anti-mouse igg best effort concentration, best confining liquid and off-period, optimum antibody incubation time and best β to be checked 2Confirming of GPI concentration finally set up β 2The detection method of GPI and test kit.
Detection β according to the invention 2The double antibodies sandwich ELISA measuring method of GPI.Its step comprises:
(1) with coating buffer CBS with the anti-people β of the rabbit of this prepared in laboratory 2The polyclonal antibody of GPI is diluted to working concentration (0.08 μ g/ μ l) and adds in the elisa plate hole, and every hole 100 μ l place 4 ℃ of refrigerator overnight;
(2) discard liquid in the hole, wash enzyme plate 5 times with washings PBST, each 5min claps dried with thieving paper;
(3) the foetal calf serum 250 μ l of adding confining liquid 10% in the hole in each elisa plate hole, 37 ℃ of effect 2h, the method for (2) washing set by step;
(4) standard substance after will diluting with the PBS diluent and plasma specimen to be measured add and are coated with in the elisa plate hole of polyclonal antibody every hole 50 μ l, 37 ℃ of effect 1h, the method for (2) washing set by step;
(5) will resist people β with the PBS diluent 2The monoclonal antibody of GPI is diluted to working concentration (0.06 μ g/ hole), and every hole adds 50 μ l, 37 ℃ of effect 1h, the method washing of repeating step (2);
(6) with washings the HRP-sheep anti-mouse igg is pressed working concentration dilution (1:10000 by volume), every hole adds 50 μ l, 37 ℃ of effect 1h, the method washing of repeating step (2);
(7) in every hole in enzyme plate hole, add A, each 50 μ l of B colour developing liquid, 37 ℃ of lucifuge colour developing 15min;
(8) in every hole in enzyme plate hole, add 50 μ l stop buffer termination reactions;
(9) on ELIASA in predominant wavelength 450nm, reference wavelength 630nm place carries out the dual wavelength colorimetric, the absorbance in the determination step (8) (OD value);
(10) drawing standard curve calculates β in the sample to be checked 2The content of GPI.Wherein:
The described elisa plate of step (1) is available from the removable enzyme plate of 96 hole single holes of Costar company;
The described coating buffer CBS of step (1) (0.05M) prepares as follows: yellow soda ash 1.59g, and sodium hydrogencarbonate 2.93g is settled to 1000ml with zero(ppm) water, transfers pH to 9.6 with HCL/NaOH;
The preparation of the said lavation buffer solution PBST of step (2) (0.15M) is following: sodium-chlor 8.0g, and Repone K 0.2g, Sodium phosphate, dibasic 0.2g, potassium primary phosphate 2.9g, polysorbas20 0.5ml is settled to 1000ml with zero(ppm) water, transfers pH to 7.4;
The said confining liquid of step (3) is prepared as follows: washings 100ml, and foetal calf serum 10ml, foetal calf serum is available from GIBCO company;
The preparation of step (4), (5) described antigen, antibody diluent PBS (0.01M) is following: SODIUM PHOSPHATE, MONOBASIC 0.39g, and Sodium phosphate, dibasic 1.27g, sodium-chlor 0.85g, zero(ppm) water is settled to 1000ml, transfers pH to 7.2;
HRP-sheep anti-mouse igg described in the step (6) is available from doctor's moral biotechnology ltd;
The said colour developing liquid of step (7) A, B, and stop buffer described in the step (8) is all from clinical laboratory of Affiliated Hospital of Jiangsu University.
Description of drawings
Fig. 1 is the anti-β of purifying 2The 12%SDS-PAGE of GPI monoclonal antibody analyzes;
Fig. 2 is the hybridoma chromosome analysis;
Fig. 3 is the subgroup identification (test strip method) of MAbs; Wherein 1,3,5 is calibration tape, and 2,4,6 is index zone, detected result IgG1/Kappa.
Fig. 4 is anti-β 2GPI monoclonal antibody specificity analyses (Western blot).
Fig. 5 is human plasma β 2The double-antibody sandwich elisa of glycoprotein I is measured the typical curve of test kit.
Hybridoma cell line AB2-F6 of the present invention delivers Chinese typical culture collection center preservation on June 14th, 2011, and deposit number is CCTCC NO:C201132; Depositary institution address: Chinese Wuhan University.
Embodiment
Following employed β 2GPI and anti-β 2The GPI polyclonal antibody is prepared by the contriver, and the preparation method sees reference respectively, and (Huang is loud and clear, Zhou Hong for document; Wang Ting, etc. beta 2 glycoprotein I purifying and stability analysis thereof [J]. the journal .2008 of Jiangsu University, 18 (4): 344-347.) with (yellow loud and clear; Zhou Hong, Yu Ying, etc. the anti-people β of rabbit 2Gp I Polyclonal Antibody Preparation and evaluation [J]. Clinical Laboratory magazine .2009,27 (3): 192-194.), the β of preparation 2GPI has identified itself and standard β 2The GPI characteristic is identical, the anti-β of preparation 2Methods such as the immune double diffusion test of GPI polyclonal antibody (IDD), EL ISA and western-bloting identify to have specificity.
Embodiment 1, anti-β 2The GPI MONOCLONAL ANTIBODIES SPECIFIC FOR
(1) mouse immune is with β 2GPI processes immunogen with saline water dilution back and equivalent Fu Shi Freund's complete adjuvant (Sigma company) after fully emulsified, nape portion subcutaneous multi-point injection BALB/c female mices in 6 age in week (50 μ g/ only, available from Yangzhou medical science Correlation Centre).Whenever all at a distance from 2 later on freund 's incomplete adjuvant (Sigma company) Isodose β 2Carry out booster immunization after the GPI emulsification 2~3 times (50 μ g/, abdominal injection).Behind the last booster immunization 7 days, blood was got in the mouse docking, surveys immunizing potency, selected the high mouse of immunizing potency in last booster immunization 20 days, with saline water dilution Isodose β 2GPI carries out the tail vein and strengthens (12.5 μ g/ only), impacts in the immunity back 3~5 days the eyeball blood sampling and keeps sample and tire with ELISA method mensuration immune serum; Extracting spleen cell is used for merging.
(2) cytogamy and hybridoma cloning SP2/0 myeloma cell (available from Shanghai biocytology institute) are in merging a few days ago enlarged culturing, and the cell of selecting logarithmic phase is used for merging.Mouse is plucked eyeball and gets blood, stays serum to make positive control, and mouse is put to death the back extracting spleen cell; Splenocyte and SP2/0 cell are mixed in fusion pipe with 4:1, centrifugal, remove supernatant; Be deposited in and drip 1mL50%PEG1450 (Sigma company) in 37 ℃ of water-baths, evenly add in the 60s, in 90s, drip 30mL serum-free RPMI1640 substratum (Gibco company) termination reaction immediately; Leave standstill 10min in 37 ℃ of water-baths, the centrifugal supernatant that goes, fused cell go into to be added with 96 orifice plates (Greiner company) of feeder cell with shop, HAT substratum (Gibco company) dilution back; Place 37 ℃, 5%CO 2Cultivate in the incubator.Begin to observe the clonal growth situation after 3 days, changed liquid with HAT substratum half amount on the 4th day, about 7 days with HT substratum (Gibco company) the HAT substratum in the hole that swaps out fully.Adopt indirect elisa method to screen, it is frozen that positive hole changes 24 well culture plate enlarged culturing over to, carries out subclone 3~4 times with limiting dilution assay simultaneously, reaches 100% enlarged culturing to positive rate, builds strain and preserve this hybridoma cell line called after AB2-F6.
(3) indirect elisa method detects anti-β 2Definite β of antigen and two anti-concentration during the GPI monoclonal antibody 2GPI is with the carbonate solution dilution back coated elisa plate of 0.05mol/L pH9.6, and confining liquid is for containing the 0.02mol/LpH7.4PBS of 10% calf serum (Gibco company).With normal mouse serum 1:1000 as negative control, with β 2The polyvalent antibody 1:2000 of GPI immunized mice is as positive control, confirms envelope antigen and the enzymic-labelled antibody (best of breed of sheep anti-mouse igg-HRP) with the square formation volumetry.The result judges: sample absorbancy (A) value is judged to the positive greater than 2.1 times of negative control A value.Top condition is: 1 μ g/ml β 2The GPI coated elisa plate, sheep anti-mouse igg-HRP working concentration 1: 10000.
(4) anti-β 2GPI MONOCLONAL ANTIBODIES SPECIFIC FOR and purifying are got 10~12 BALB/c mouse abdominal injection whiterusss in age in week (0.5mL/ only), 7~10 days pneumoretroperitoneum injection hybridoma AB2-F6 (0.5~1 * 10 6/ only), extract ascites about 7~14 days, be stored in-70 ℃ of refrigerators after the packing.Adopt ammonium sulfate precipitation and Protein G purifying ascites, identify purity with SDS-PAGE.Press experimental formula: protein concentration (mgmL)=1.45 * A 280-0.74 * A 260Calculate the protein concentration and the yld of purifying front and back.SDS-PAGE operates by ordinary method, 12% separation gel, and 5% concentrates glue, and AC 1mgmL mixes with the reduced form sample loading buffer of equivalent, 100 ℃ of 5min, appearance on the 25 μ L/ holes, constant current 50mA electrophoresis, 0.25% coomassie brilliant blue staining carries out albumen scanning.Analytical results is seen Fig. 1, and swimming lane is an electrophoresis result under the reductive condition, is respectively heavy chain immunoglobulin (about 50KD) and light chain (about 25KD), and the purity of ascites monoclonal antibody is more than 90%.
Embodiment 2, anti-β 2The evaluation of GPI monoclonal antibody
(1) evaluation of monoclonal antibody prevents method to obtain the hybridoma (AB2-F6) of more metaphase with NST-757, and again through hypotonic, after fixing the processing, with the dyeing of 10%Giemsa dye liquor, mirror is observed karyomit(e) down.Show that like Fig. 2 the hybridoma chromosome number is more than 51 of the SP2/0 cell, between the 99-108 bar.Tire with indirect elisa method mensuration cells and supernatant and ascites, the indirect elisa method result shows that the ascites monoclonal antibody behind the cleer and peaceful purifying is to β on the Hybridoma Cell Culture 2The titre of GPI was respectively 1: 2 9With 1: 2 15Identify Ig subclass (by specification operation), showed cell IgG secretion 1/Kappa type antibody (Fig. 3) as a result with monoclonal antibody subgroup identification test kit.Identify anti-β with Western blot 2The specificity of GPI monoclonal antibody: with sample loading buffer with β 2GPI is mixed with 1mg/mL, and 12%SDS-PAGE electrophoretic separation albumen is transferred to pvdf membrane with the 350mA constant current again; Film places the TBS/T room temperature sealing 1h that contains 5% skimmed milk; With film respectively with the β of the present invention of 1:1000 dilution 2GPI monoclonal antibody and standard β 2GPI monoclonal antibody (MAB1066, U.S. Chemicon company) reaction, inferior daily TBS/T washing 3 times, 15min/ time; Adopt the sheep anti-mouse igg antibody (1:2000) of HRP mark, hatch 1h for 37 ℃, TBS/T washing 3 times; 15min/ time, the hybridization band is observed in ECL Color Appearance System photographic fixing colour developing.The result sees Fig. 4: figure A is anti-β of the present invention 2GPI monoclonal antibody reactive result, result show anti-β of the present invention 2The β of about 45KD on GPI monoclonal antibody and the pvdf membrane 2GPI antigen reacts, and does not have significant reaction with the BSA at 67KD place, explains that monoclonal antibody only discerns β 2GPI, specificity is good, the standard anti-β of figure B for buying 2GPI monoclonal antibody reactive (positive control).
(2) frozen 6 months cell strain AB2-F6 in the evaluation recovery liquid nitrogen container of hybridoma cell strain passes through the abdominal injection BALB/c mouse with cell after enlarged culturing, collect ascites and survey it to β 2The ELISA titre of GPI is observed hybridoma and is secreted anti-β 2The stability of GPI monoclonal antibody; Chromosome examination is undertaken by ordinary method.The result shows the anti-β of AB2-F6 stably excreting 2The GPI monoclonal antibody, and the hybridoma chromosome number is between the 99-108 bar.
Embodiment 3, human plasma β 2The foundation of GPI double-antibody sandwich elisa test kit
(1) chooses suitable encapsulant
Experiment is divided into three groups, and wherein every group is divided into again and does not encapsulate a closed group and add closed group with encapsulating, and chooses three confining liquids commonly used and is mixed with 5% skim-milk with PBST respectively; 2% bovine serum albumin, 10% foetal calf serum (FBS) seal above three groups respectively, and the result shows; Preceding two confining liquid sealing effects are not good; Stronger non-specific colour developing is arranged, and the 10%FBS sealing effect is better, does not almost have non-specific colour developing.
(2) anti-people β 2Confirming of GPI list/polyclonal antibody and HRP-sheep anti-mouse igg best effort concentration
Utilize the chessboard titration to confirm the best effort concentration of each component.Because present method belongs to indirect double antibodies sandwich method, need to confirm the best effort concentration of three components, so chessboard titration at twice:
1. for the first time titration, the fixedly concentration of coated antibody and ELIAS secondary antibody: with the conservative relatively anti-β that measures 0.05 μ g/ μ l 2GPI polyclonal antibody 100 μ l encapsulate elisa plate, and 4 ℃ encapsulate and spend the night; Next day, with PBST washing 5 times, 1min/ time, thieving paper is clapped and is done; Every hole adds 250 μ l10%FBS, 37 ℃ of sealing 2h; After the same washing, elisa plate lateral variation antigen β 2The concentration of GPI adds a blank again with 1 μ g/ μ l, 0.2 μ g/ μ l, 0.04 μ g/ μ l, 0.008 μ g/ μ l and l5 gradient of 0.0016 μ g/ μ respectively and promptly only adds PBS by in every hole 50 μ l adding micropore, 37 ℃ of incubation 1h; After the washing; Vertically change the monoclonal anti bulk concentration; Add one 0 concentration again with 0.04 μ g/ μ l, 0.02 μ g/ μ l, 0.01 μ g/ μ l, 0.005 μ g/ μ l, 0.0025 μ g/ μ l, 0.0012 μ g/ μ l, l7 gradient of 0.0006 μ g/ μ respectively and add micropore, 37 ℃ of incubation 1h by every hole 50 μ l; After the washing, every hole adds the HRP-sheep anti-mouse igg 50 μ l with 8000 times of PBST dilutions, 37 ℃ of incubation 0.5h; Behind the thorough washing, every hole adds A, each 50 μ l of B substrate solution, and behind 37 ℃ of reaction 15min, every hole adds 50 μ l stop buffer termination reactions, and it is 450nm that ELIASA reads predominant wavelength, and reference wavelength is the absorbance at 630nm place.With SNR (containing measured OD value of analyte and the ratio that does not contain the measured OD value of analyte) the pairing antigen-antibody concentration of the maximum is best effort concentration.The result sees table 1
Table 1 is the chessboard titration results for the first time
Figure BDA00001922258300071
2. carry out titration for the second time according to antigen and an anti-best effort concentration that the first time, the chessboard titration drew: the polyclonal antibody concentration that lateral variation encapsulates; Encapsulate elisa plate with 0.1 μ g/ μ l, 0.08 μ g/ μ l, 0.06 μ g/ μ l, 0.04 μ g/ μ l, 0.02 μ g/ μ l, 0 μ g/ μ l respectively; 100 μ l/ holes, 4 ℃ are spent the night; Next day, after the same washing of PBST, every hole adds 250 μ l10%FBS, 37 ℃ of sealing 2h; After the washing, every hole adds the antigen β of 50 μ l0.2 μ g/ μ l 2GPI, 37 ℃ of incubation 1h; After the washing, every hole adds the monoclonal antibody of 50 μ l0.0012 μ g/ μ l, 37 ℃ of incubation 1h; After the washing, vertically change the concentration of HRP-sheep anti-mouse igg, add the HRP-sheep anti-mouse igg of 50 μ l respectively, 37 ℃ of incubation 0.5h with 6000,8000,10000,12000 times of PBST dilutions; Behind the thorough washing, every hole adds A, each 50 μ l of B substrate solution, and behind 37 ℃ of reaction 15min, every hole adds 50 μ l stop buffer termination reactions, and it is 450nm that ELIASA reads predominant wavelength, and reference wavelength is the absorbance at 630nm place.Obtain much more best anti-and two anti-concentration according to above result treatment mode.The result sees the following form 2
Table 2 is the chessboard titration results for the second time
Figure BDA00001922258300072
Figure BDA00001922258300081
After twice chessboard titration, draw top condition and be: the anti-β of 0.08 μ g/ μ l 2The GPI polyclonal antibody encapsulates elisa plate, and the monoclonal antibody working concentration is 0.0012 μ g/ μ l, and HRP-sheep anti-mouse igg working concentration is 1:10000.
Embodiment 4, human plasma β 2The preparation of GPI double-antibody sandwich elisa test kit typical curve
With the anti-β of 50 μ l0.08 μ g/ μ l 2The GPI polyclonal antibody encapsulates elisa plate, and 4 ℃ encapsulate and spend the night; Next day, with PBST washing 5 times, 1min/ time, every hole adds 250 μ l10%FBS, 37 ℃ of sealing 2h; After the same washing, add the standard substance β of different weaker concns 2GPI is with standard substance β 2It is 10ng/ μ l, 20ng/ μ l, 40ng/ μ l, 80ng/ μ l, 160ng/ μ l that GPI is diluted to concentration, establishes negative control simultaneously and (carries β 2Cross post liquid during GPI) and blank (PBS), 37 ℃ of incubation 1h; After the washing, add the anti-β of 50 μ l0.0012 μ g/ μ l 2The GPI monoclonal antibody, 37 ℃ of incubation 1h; After the washing, every hole adds the HRP-sheep anti-mouse igg of 50 μ l1:10000 dilution, 37 ℃ of incubation 0.5h; Behind the thorough washing, every hole adds A, each 50 μ l of B substrate solution, and behind 37 ℃ of reaction 15min, every hole adds 50 μ l stop buffer termination reactions, and it is 450nm that ELIASA reads predominant wavelength, and reference wavelength is the absorbance at 630nm place.Based on colorimetric drawing standard curve as a result, see Fig. 5.
Embodiment 5, human plasma β 2The application of GPI double-antibody sandwich elisa test kit
With human plasma β of the present invention 2The GPI double-antibody sandwich elisa is measured test kit and is detected clinical samples, is divided into 2 test set: normal healthy controls and APS patient's group.In advance with sample with 5 times of PBS dilutions, then with test kit detection according to the invention, concrete steps are with described in the embodiment 2, ELIASA colorimetric result such as table 3:
Table 3 human plasma β 2The double-antibody sandwich elisa of glycoprotein I is measured the result of kit measurement sample
Figure BDA00001922258300082
Figure BDA00001922258300091

Claims (4)

1. anti-people β of IgG1 type 2The monoclonal antibody of glycoprotein I is characterized in that said monoclonal antibody by hybridoma cell line AB2-F6 secretion, and the preserving number of said hybridoma cell line AB2-F6 is CCTCC NO:C201132.
2. one kind prepares the anti-people β of IgG1 type 2The glycoprotein I monoclonal antibody method is characterized in that may further comprise the steps: prepare ascites with being injected into BALB/c mouse after the hybridoma AB2-F6 enlarged culturing, ascites obtains anti-β behind ammonium sulfate precipitation and Protein G purifying 2The glycoprotein I monoclonal antibody.
3. the anti-people β of the said IgG1 type of claim 1 2The monoclonal antibody of glycoprotein I is at preparation human plasma β 2The double-antibody sandwich elisa of glycoprotein I is measured the application in the test kit.
4. human plasma β 2The double-antibody sandwich elisa of glycoprotein I is measured test kit, it is characterized in that by anti-β 2The elisa plate that the GPI polyclonal antibody encapsulates, 10% foetal calf serum confining liquid, the described anti-β of claim 1 2GPI monoclonal antibody, HRP-sheep anti-mouse igg, colour developing liquid and stop buffer are formed.
CN2012102560047A 2011-07-28 2012-07-23 IgG1 anti-human beta2-glycoprotein I monoclonal antibody, and preparation and application thereof Pending CN102816238A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012102560047A CN102816238A (en) 2011-07-28 2012-07-23 IgG1 anti-human beta2-glycoprotein I monoclonal antibody, and preparation and application thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110213815.4 2011-07-28
CN201110213815 2011-07-28
CN2012102560047A CN102816238A (en) 2011-07-28 2012-07-23 IgG1 anti-human beta2-glycoprotein I monoclonal antibody, and preparation and application thereof

Publications (1)

Publication Number Publication Date
CN102816238A true CN102816238A (en) 2012-12-12

Family

ID=47300715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012102560047A Pending CN102816238A (en) 2011-07-28 2012-07-23 IgG1 anti-human beta2-glycoprotein I monoclonal antibody, and preparation and application thereof

Country Status (1)

Country Link
CN (1) CN102816238A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015004038A1 (en) * 2013-07-10 2015-01-15 Onconox Aps ANTIBODIES TO β2-GLYCOPROTEIN I AND THERAPEUTIC USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101434653A (en) * 2008-11-28 2009-05-20 安徽医科大学 Preparation and detection kit for human ARMET protein monoclonal antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101434653A (en) * 2008-11-28 2009-05-20 安徽医科大学 Preparation and detection kit for human ARMET protein monoclonal antibody

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
《British Journal of Haematology》 19921231 J .Arvieux, et al. Lupus-like anticoagulant properties of murine monoclonal antibodies to beta2-glycoprotein I 568-573 2 , *
《Journal of Immunological Methods》 19981231 Ve�ronique Regnault, et al. Immunopurification of human beta2-glycoprotein I with a monoclonal antibody selected for its binding kinetics using a surface plasmon resonance biosensor 191-197 1-4 , *
《临床检验杂志》 20091231 黄宏亮 等 兔抗人beta2糖蛋白I多克隆抗体的制备与鉴定 192-194 1-4 第27卷, 第3期 *
J .ARVIEUX, ET AL.: "Lupus-like anticoagulant properties of murine monoclonal antibodies to β2-glycoprotein I", 《BRITISH JOURNAL OF HAEMATOLOGY》 *
VE´RONIQUE REGNAULT, ET AL.: "Immunopurification of human β2-glycoprotein I with a monoclonal antibody selected for its binding kinetics using a surface plasmon resonance biosensor", 《JOURNAL OF IMMUNOLOGICAL METHODS》 *
黄宏亮 等: "兔抗人β2糖蛋白I多克隆抗体的制备与鉴定", 《临床检验杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015004038A1 (en) * 2013-07-10 2015-01-15 Onconox Aps ANTIBODIES TO β2-GLYCOPROTEIN I AND THERAPEUTIC USES THEREOF
US9777057B2 (en) 2013-07-10 2017-10-03 Onconox Aps Antibodies to β2-glycoprotein I and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
CA1247539A (en) Method for detecting immune complexes in serum
Watters et al. Organization of ligand binding sites at the acetylcholine receptor: a study with monoclonal antibodies
US9933433B2 (en) Anti-drug antibody assay
US5084380A (en) Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
CN101906159B (en) Hybridoma cell line D6D
CN110407937A (en) A kind of preparation and its application of anti-AMH monoclonal antibody
CN106483303A (en) Human blood types detection kit and preparation method thereof
Woodard et al. Characterization of epitopes of human secretory component on free secretory component, secretory IgA, and membrane-associated secretory component.
EP0142345A2 (en) Anti-idiotypic vaccine employing anti-idiotypic monoclonal antibodies
CN109082413A (en) Anti-human igg monoclonal antibody, its hybridoma cell strain and application
CA1296660C (en) Monoclonal antibody against a ras oncogene p21 related dodecapeptide
CN102816238A (en) IgG1 anti-human beta2-glycoprotein I monoclonal antibody, and preparation and application thereof
CN109956848A (en) A kind of triclosan haptens and antigen and its preparation method and application
CN112574956A (en) Hybridoma cell strain secreting propamocarb monoclonal antibody and application thereof
KR940010021B1 (en) Monoclonal antibodies against atrial natriuretic peptides
EP0401370B1 (en) Enzyme immunoassay according to sandwich method of human iv-type collagen
CN106754742B (en) Hybridoma cell strain of anti-microcystin antibody and monoclonal antibody secreted by same
Killefer et al. Production of a novel monoclonal antibody to porcine adipocyte plasma membrane
CN114134123B (en) Monoclonal antibody of pregnancy related glycoprotein and application thereof in early pregnancy detection of cattle
Dobloug et al. Demonstration of rheumatoid factor idiotypic antigens on peripheral blood B and T lymphocytes from patients with rheumatoid arthritis
CN100462432C (en) Hybridoma cell strain, and anti-human heparin enzyme monoclonal anti-body produced by it
CN110218703A (en) A kind of antigen-specific b cells screening technique and its application in monoclonal antibody preparation
CN114047340A (en) Application of human ApoC1 full-length protein in preparation of autism diagnosis kit and kit
EP3548899B1 (en) Rapid semiquantitative method for determining adamts-13 activity in a patient plasma sample
CA2254151A1 (en) Method for immunological assay

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121212